<DOC>
	<DOC>NCT01574651</DOC>
	<brief_summary>This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.</brief_summary>
	<brief_title>The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male or female adults aged ≥ 40 yrs Patients with moderate to severe chronic obstructive pulmonary disease (GOLD 2010 guidelines) Smoking history of at least 10 pack years Postbronchodilator FEV1 &lt; 80% and ≥30% of the predicted normal value and postbronchodilator FEV1/FVC (forced vital capacity) &lt;70% Pregnant women or nursing mothers or women of childbearing potential not using adequate contraception Patients with a history of long QT syndrome Patients with Type I or uncontrolled Type II diabetes Patients who have had a COPD exacerbation or respiratory tract infection within 6 weeks prior to screening Patients with any history of asthma Patients with pulmonary lobectomy, lung volume reduction surgery, or lung transplantation Patients with concomitant pulmonary disease Patients requiring long term oxygen therapy (&gt;15 h a day) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>QVA149</keyword>
	<keyword>Health related quality of life</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Tiotropium</keyword>
	<keyword>COPD</keyword>
</DOC>